Two others found that treatment with the device significantly reduced per-patient cost of COPD exacerbations, recurrence of exacerbations within 30 days post-discharge, and the use of antibiotics (57%) and oral corticosteroids (89%) for hospitalized COPD patients.
One study found significant improvements in ventilation function for bronchiectasis patients after three weeks of Aerobika use. Three recent studies 6, 7, 8 have reported positive results for Aerobika for COPD and bronchiectasis patients. Monaghan Medical’s Aerobika oscillating positive expiratory pressure (OPEP) device assists mucociliary clearance and helps prevent COPD progression, according to the company. Threshold PEP may also help improve gas exchange and medication deposition when used in conjunction with nebulizer treatments, according to Philips. The device has a flow-dependent, one-way valve, and, according to the company, this allows it to maintain a constant pressure, regardless of the patient’s airflow, which means a pressure indicator is not required. 4 Weighing only 1.3 oz, Threshold PEP is indicated for pediatric and adult therapy. Threshold PEP, manufactured by Philips Respironics, is used for airway clearance therapy, bronchial hygiene, or in place of chest physical therapy, according to the company. Therapy can be administered while seated, standing or reclined, and can be used with a mask or mouthpiece attachment, as well as an inline nebulizer. Smiths Medical also offers the acapella DM & DH Vibratory PEP Therapy System, which can prolong expiratory airflow to increase removal of secretions. 3 TheraPEP therapy can be self-administered in any setting, in less than half the time required for CPT, according to the company. 2 Acapella and TheraPEPĪvailable from Smiths Medical, the TheraPEP device is designed to treat CF and other lung diseases with secretory problems, to prevent or reverse atelectasis, and as a therapy for patients recovering from surgery.
The therapy is “goal-based” and ends when no more mucus can be expectorated, with therapy lasting approximately 5-15 minutes. According to Aptalis, the therapy is administered in two stages: (1) mucus loosening and mucus mobilization, and (2) mucus elimination. 2įlutter functions by vibrating the airways, intermittently increasing endobronchial pressure, and accelerating expiratory airflow. The Flutter mucus clearance device, manufactured by Aptalis Pharma US Inc, provides PEP therapy for patients with atelectasis, bronchitis, bronchiectasis, cystic fibrosis, COPD, asthma or other conditions producing retained secretions, according to the company. 1 In this article, RT takes a look at some of the latest PEP devices available on the market, including some new oscillating PEP (OPEP) devices. It also holds airways open, keeping them from closing,” according to the Cystic Fibrosis Foundation. The therapy, which is administered by breathing through a special device, “helps air get behind the mucus and helps move it from lung and airway walls. One of the most frequently prescribed airway clearance therapy (ACT) options for patients with chronic lung conditions is positive expiratory pressure therapy (PEP). Long-term studies of the use of the Flutter seem justified to determine its effects on pulmonary function and outcome.One of the most frequently prescribed airway clearance therapy (ACT) options for patients with chronic lung conditions is positive expiratory pressure therapy (PEP). For hospitalized patients, elimination of the need for a therapist could reduce health care costs. The Flutter is simple to use, inexpensive, and fully portable, and once the patient and family are instructed in its use, it does not require the assistance of a caregiver. The amount of sputum expectorated by subjects using the Flutter was more than three times the amount expectorated with either voluntary cough or postural drainage (p < 0.001). The amount of sputum expectorated (measured by weight) when the Flutter was used was compared with the amount expectorated with vigorous voluntary coughing and with postural drainage (chest percussion and vibration). We studied 18 patients with cystic fibrosis and mild to moderate lung disease to determine the efficacy of the Flutter in clearing mucus from the airways. Exhalation through the Flutter results in oscillations of expiratory pressure and airflow, which vibrate the airway walls (loosening mucus), decrease the collapsibility of the airways, and accelerate airflow, facilitating movement of mucus up the airways.
The Flutter is a handheld device designed to facilitate clearance of mucus in hypersecretory lung disorders.
0 kommentar(er)
